An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I ("High Need") and GROUP II ("Low Need") Patients Suffering From Chronic Plaque Psoriasis (Psoriasis Vulgaris).
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2013
At a glance
- Drugs Infliximab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms IHELP
- Sponsors Merck & Co
- 12 Jul 2011 Additional trial location added as reported by European Clinical Trials Database.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
- 22 Jul 2010 New trial record